Mumbai, November 13, 2025: Global pharma leader Lupin Limited (Lupin) today announced that it has achieved an S&P Global ESG Score of 91 for 2025, well above the pharmaceutical industry average of 28. Lupin is now part of an exclusive group of companies worldwide that have surpassed the 90-point mark.*

This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth.

Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said, “Achieving a score above 90 in the S&P Global ESG ratings is rare global distinction, highlighting our unwavering commitment to sustainability. With a 15-point increase from last year, Lupin not only leads the pharmaceutical industry today, but redefines and sets new standards for responsible growth. Our purpose-led strategy ensures that we provide healthcare solutions that generate lasting value for patients, communities, and stakeholders worldwide.”

Lupin has made significant progress across all three pillars – Environmental, Social, and Governance. The company has intensified its environmental efforts by increasing the use of renewable energy, successfully reducing carbon emissions, and achieving water-positive operations. On the social front, Lupin has prioritized employee well-being by promoting diversity and inclusion, launching community health programs, and making significant contributions to societal healthcare. In terms of governance, the organization has enhanced transparency, upheld ethical business practices, fortified corporate governance, and instituted board-level oversight to address ESG-related risks and opportunities effectively.

About Lupin
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 24,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
To know more, visit www.lupin.com  or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries, please contact 
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications, Lupin
rajalakshmiazariah@lupin.com